LIST OF TABLES

Sr. No.	Titles	Page No.
Chapter 2: Literature Review		
Table 2.1	Dermal infections and antimicrobial proteins/peptides used	22
Chapter 3: Analytical Method		
Table 3.1	List of materials	53
Table 3.2	List of instruments	53
Table 3.3	Peak area data of Omiganan at initial and 24 h for calibration and stability	59
Table 3.4	Accuracy of the HPLC method for Omiganan	59
Table 3.5	Intraday & interday precision analysis of HPLC method of Omiganan	60
Table 3.6	Sensitivity evaluation of HPLC method of Omiganan	60
Table 3.7	area data of DPK-060 at initial and 24 h for calibration and stability	62
Table 3.8	Accuracy of the HPLC method for DPK-060	63
Table 3.9	Intraday and interday precision analysis of HPLC method of DPK-060	63
Table 3.10	Sensitivity evaluation of HPLC method of DPK-060	64
Chapter 4: Preformulation study		
Table 4.1	List of materials	66
Table 4.2	List of instruments	67
Table 4.1	Mixture components and their ratio for drug-excipient compatibility assessment	69
Chapter 5A) Formulation Development: Omiganan Nano-lipid Constructs		
Table 5A.1	List of materials	78
Table 5A.2	List of instruments	78
Table 5A.3	List of variables mainly affecting Omiganan NLC formulation	80
Table 5A.4	Selected values of variables for BBD	81
Table 5A.5	Formulation components and concentration used in the	83

	preparation of Omiganan NLC gel	
Table 5A.6	Randomized BBD design matrix generated by Design-Expert software	86
Table 5A.7	Statistical analysis of design for % Drug entrapment	87
Table 5A.8	ANOVA for Response Surface Quadratic Model for % Drug entrapment	87
Table 5A.9	ANOVA study results for % Drug entrapment	89
Table 5A.10	Statistical analysis of design for Particle size	93
Table 5A.11	ANOVA for Response Surface Quadratic Model for Particle size	94
Table 5A.12	ANOVA study results for Particle size	95
Table 5A.13	Variables for desirability plot and goals for response	100
Table 5A.14	Desirability Plot for Optimization solution for Omiganan nano-lipid constructs	101
Table 5A.15	Results of Evaluation of desirability batch	101
Table 5A.16	Composition of optimized batch of Omiganan NLCs and gel	102
Chapter 5B) Formulation Development: Omiganan Liposomes		
Table 5B.1	List of materials	110
Table 5B.2	List of instruments	110
Table 5B.3	List of variables mainly affecting Omiganan liposomal formulation	112
Table 5B.4	Selected values of variables for BBD	112
Table 5B.5	Formulation components with their concentration used in the preparation of Omiganan liposomal gel	114
Table 5B.6	Randomized BBD design matrix generated Design-Expert software	117
Table 5B.7	Statistical analysis of design for % Drug entrapment	118
Table 5B.8	ANOVA for Response Surface Quadratic Model for % Drug entrapment	119
Table 5B.9	ANOVA study results for % Drug entrapment	120
Table 5B.10	Statistical analysis of design for Vesicle size	125

Table 5B.11	ANOVA for Response Surface Quadratic Model for Vesicle size	125
Table 5B.12	ANOVA study results for vesicle size	127
Table 5B.13	Variables for desirability plot and goals for response	131
Table 5B.14	Desirability Plot for Optimization solution for Omiganan liposomes	132
Table 5B.15	Results of Evaluation of desirability batch	132
Table 5B.16	Composition of optimized batch of Omiganan liposomes and gel	134
Chapter 5C) Formulation Development: Omiganan Lotion		
Table 5C.1	List of materials	140
Table 5C.2	List of instruments	141
Table 5C.3	Optimized Batch of Omiganan lotion	142
Chapter 6A) Formulation Development: DPK-060 Nano-lipid Constructs		
Table 6A.1	List of materials	147
Table 6A.2	List of instruments	147
Table 6A.3	List of variables mainly affecting DPK-060 NLC formulation	149
Table 6A.4	Selected values of variables for BBD	149
Table 6A.5	Formulation components with their concentration used in the preparation of DPK-060 NLC gel	151
Table 6A.6	Randomized BBD design matrix generated by Design-Expert software	154
Table 6A.7	Statistical analysis of design for % Drug entrapment	155
Table 6A.8	ANOVA for Response Surface Quadratic Model for % Drug entrapment	155
Table 6A.9	ANOVA study results for % Drug entrapment	157
Table 6A.10	Statistical analysis of design for Particle size	161
Table 6A.11	ANOVA for Response Surface Quadratic Model for Particle size	162

Table 6A.12	ANOVA study results for Particle size	163
Table 6A.13	Variables for desirability plot and goals for response	168
Table 6A.14	Desirability Plot for Optimization solution for DPK-060 nano-lipid constructs	169
Table 6A.15	Results of Evaluation of desirability batch	169
Table 6A.16	Composition of optimized batch of DPK-060 NLCs and gel	171
Chapter 6B) Formulation Development: DPK-060 Lotion		
Table 6B.1	List of materials	177
Table 6B.2	List of instruments	178
Table 6B.3	Optimized Batch of DPK-060 lotion	179
Chapter 7 *In-vitro* and *ex-vivo* studies		
Table 7.1	*In-vitro* drug release study of Omiganan loaded formulations	190
Table 7.2	*In-vitro* drug release study of DPK 060 loaded formulations	190
Table 7.3	Various mathematical models and their correlation coefficient (r^2) values	192
Table 7.4	Various mathematical models and their correlation coefficient (r^2) values	193
Table 7.5	*In vitro* cell viability data for Omiganan and DPK 060 formulations in 3T3-fibroblast cells	194
Table 7.6	MIC values of different formulations of Omiganan and DPK 060 against *S. aureus* and *C. albicans*	199
Table 7.7	*Ex-vivo* drug permeation and retention of Omiganan loaded formulations	203
Table 7.8	*Ex-vivo* drug permeation and retention of DPK 060 loaded formulations	203
Chapter 8 *In-vivo* studies		
Table 8.1	Treatment groups for anti-psoriatic efficacy in Imiquimod induced psoriatic animal model in BALB/C mice	212

Table 8.2	Different treatment groups for anti-eczematic efficacy in Ovalbumin induced animal model in BALB/C mice	214
Chapter 9 Stability Study		
Table 9.2	Stability study of Omiganan and DPK 060 loaded formulations	232